Pravastatin attenuates interferon-γ action via modulation of stat1 to prevent aortic atherosclerosis in apolipoprotein E-knockout mice

Clinical and Experimental Pharmacology and Physiology

Volumn 36, Issue 4, 2009, Pages 373-379

  Zhou, Xiao Xu ^a   Gao, Ping Jin ^a   Sun, Bao Gui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Atherosclerosis; Interferon regulating factor 1; Interferon ; Pravastatin; Signal transducer and activator of transcription 1; Suppressors of cytokine signalling 1

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PRAVASTATIN; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HISTOPATHOLOGY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; WESTERN BLOTTING;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; HYPOLIPIDEMIC AGENTS; INTERFERON REGULATORY FACTOR-1; INTERFERON-GAMMA; LIPIDS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PRAVASTATIN; STAT1 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 68849089686     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.05067.x     Document Type: Article

References (42)

1. Libby P. Inflammation in atherosclerosis. Nature 2002 420 : 868 74.
2. Veillard NR, Steffens S, Burger F, Pelli G, Mach F. Differential expression patterns of proinflammatory and antiinflammatory mediators during atherogenesis in mice. Arterioscler. Thromb. Vasc. Biol. 2004 24 : 2339 44.
3. Veillard NR, Braunersreuther V, Arnaud C et al. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 2006 188 : 51 8.
4. Wang XQ, Panousis CG, Alfaro ML, Evans GF, Zuckerman SH. Interferon-gamma-mediated downregulation of cholesterol efflux and ABC1 expression is by the Stat1 pathway. Arterioscler. Thromb. Vasc. Biol. 2002 22 : E5 9.
5. Leon ML, Zuckerman SH. Gamma interferon: A central mediator in atherosclerosis. Inflamm. Res. 2005 54 : 395 411.
6. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: An overview of signals, mechanisms and functions. J. Leukoc. Biol. 2004 75 : 163 89.
7. Agrawal S, Febbraio M, Podrez E, Cathcart MK, Stark GR, Chisolm GM. Signal transducer and activator of transcription 1 is required for optimal foam cell formation and atherosclerotic lesion development. Circulation 2007 115 : 2939 47.
8. Ramana CV, Chatterjee-Kishore M, Nguyen H, Stark GR. Complex roles of Stat1 in regulating gene expression. Oncogene 2000 19 : 2619 27.
9. Storm van's Gravesande K, Layne MD, Ye Q et al. IFN regulatory factor-1 regulates IFN-gamma-dependent cathepsin S expression. J. Immunol. 2002 168 : 4488 94.
10. Sun J, Marx SO, Chen HJ, Poon M, Marks AR, Rabbani LE. Role for p27 (Kip1) in vascular smooth muscle cell migration. Circulation 2001 103 : 2967 72.
11. Wessely R, Paschalidis M, Wagenpfeil S, Wegener F, Neumann FJ, Theiss W. A comprehensive approach to visual and functional assessment of experimental vascular lesions in vivo. Am. J. Physiol. Heart Circ. Physiol. 2004 286 : H2461 7.
12. Starr R, Willson TA, Viney EM et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997 387 : 917 21.
13. Endo TA, Masuhara M, Yokouchi M et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997 387 : 921 4.
14. Naka T, Narazaki M, Hirata M et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997 387 : 924 9.
15. Yasukawa H, Misawa H, Sakamoto H et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 1999 18 : 1309 20.
16. Krebs DL, Hilton DJ. SOCS : Physiological suppressors of cytokine signaling. J. Cell Sci. 2000 113 : 2813 19.
17. Auer J, Berent R, Weber T, Eber B. Clinical significance of pleiotropic effects of statins: Lipid reduction and beyond. Curr. Med. Chem. 2002 9 : 1831 50.
18. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996 348 : 1079 82.
19. Bustos C, Hernández-Presa MA, Ortego M et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J. Am. Coll. Cardiol. 1998 32 : 2057 64.
20. Takeuchi S, Kawashima S, Rikitake Y et al. Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC. Biochem. Biophys. Res. Commun. 2000 269 : 97 102.
21. Liao JK. Beyond lipid lowering: The role of statins in vascular protection. Int. J. Cardiol. 2002 86 : 5 18.
22. Mach F. Statins as immunomodulators. Transplant. Immunol. 2002 9 : 197 200.
23. Hakamada-Taguchi R, Uehara Y, Kuribayashi K et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ. Res. 2003 93 : 948 56.
24. Wakizono R, Suzuki J-I, Ogawa M et al. HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation. Cardiovasc. Res. 2004 64 : 412 20.
25. Youssef S, Stuve O, Patarroyo JC et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002 420 : 78 84.
26. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 2000 6 : 1399 402.
27. Sadeghi MM, Tiglio A, Sadigh K et al. Inhibition interferon-gamma- mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation 2001 71 : 1262 8.
28. Chung HK, Lee IK, Kang H, Suh JM et al. Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp. Mol. Med. 2002 34 : 451 61.
29. Aprahamian T, Bonegio R, Rizzo J et al. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J. Immunol. 2006 177 : 3028 34.
30. Zadelaar S, Kleemann R, Verschuren L et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler. Thromb. Vasc. Biol. 2007 27 : 1706 21. (Pubitemid 47207165)
31. Hong F, Jaruga B, Kim WH et al. Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: Regulation by SOCS. J. Clin. Invest. 2002 110 : 1503 13.
32. Lowry O, Rosenbraugh N, Farr L, Rondall R. Protein measurement with the folin-phenol reagent. J. Biol. Chem. 1951 193 : 265 75.
33. Sparrow CP, Burton CA, Hernandez M et al. Simvastatinhas anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler. Thromb. Vasc. Biol. 2001 21 : 115 21.
34. Endo A, Tsujita Y, Kuroda M, Tanzawa K. Effects of ML-236B on cholesterol metabolism in mice and rats: Lack of hypocholesterolemic activity in normal animals. Biochim. Biophys. Acta 1979 575 : 266 76.
35. Kita T, Brown MS, Goldstein JL. Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J. Clin. Invest. 1980 66 : 1094 100.
36. Bea F, Blessing E, Bennett B, Levitz M, Wallace EP, Rosenfeld ME. Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering. Arterioscler. Thromb. Vasc. Biol. 2002 22 : 1832 7.
37. Johnson J, Carson K, Williams H et al. Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: Model characterization and effects of pravastatin treatment. Circulation 2005 111 : 1422 30.
38. Watanabe S, Mu W, Kahn A et al. Role of JAK/STAT pathway in IL-6-induced activation of vascular smooth muscle cells. Am. J. Nephrol. 2004 24 : 387 92. (Pubitemid 39279379)
39. Townsend KP, Shytle DR, Bai Y et al. Lovastatin modulation of microglial activation via suppression of functional CD40 expression. J. Neurosci. Res. 2004 78 : 167 76.
40. Horiuchi M, Hayashida W, Akishita M et al. Interferon-gamma induces AT(2) receptor expression in fibroblasts by Jak/STAT pathway and interferon regulatory factor-1. Circ. Res. 2000 86 : 233 40.
41. Huang KC, Chen CW, Chen JC, Lin WW. Statins induce suppressor of cytokine signaling-3 in macrophages. FEBS Lett. 2003 555 : 385 9.
42. Mulhaupt F, Matter CM, Kwak BR et al. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc. Res. 2003 59 : 755 66.